Back to top

Image: Bigstock

Strength Seen in BioCryst (BCRX): Can Its 5.5% Jump Turn into More Strength?

Read MoreHide Full Article

BioCryst Pharmaceuticals (BCRX - Free Report) shares ended the last trading session 5.5% higher at $9.62. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 1% gain over the past four weeks.

The rise in share prices may be attributable to positive investor expectations for BioCryst's BCX9250 following the FDA granting it Fast Track designation earlier this month.

This drugmaker is expected to post quarterly loss of $0.36 per share in its upcoming report, which represents a year-over-year change of -50%. Revenues are expected to be $63.92 million, up 28% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For BioCryst, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on BCRX going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

BioCryst is part of the Zacks Medical - Drugs industry. United Therapeutics (UTHR - Free Report) , another stock in the same industry, closed the last trading session 0.8% higher at $219.38. UTHR has returned 16.8% in the past month.

United Therapeutics' consensus EPS estimate for the upcoming report has changed +5.4% over the past month to $4.12. Compared to the company's year-ago EPS, this represents a change of +12.9%. United Therapeutics currently boasts a Zacks Rank of #3 (Hold).


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


BioCryst Pharmaceuticals, Inc. (BCRX) - free report >>

United Therapeutics Corporation (UTHR) - free report >>

Published in